Florida Senate - 2017 CS for SB 1002
By the Committee on Criminal Justice; and Senators Perry,
Rouson, and Bradley
591-02931-17 20171002c1
1 A bill to be entitled
2 An act relating to the Florida Comprehensive Drug
3 Abuse Prevention and Control Act; creating s. 893.015,
4 F.S.; specifying the chapter’s purpose; providing that
5 a reference to ch. 893, F.S., or to any section or
6 portion thereof, includes all subsequent amendments;
7 amending s. 893.03, F.S.; specifying that ioflupane
8 (123I) is not included in Schedule II of the standards
9 and schedules of controlled substances; providing an
10 effective date.
11
12 Be It Enacted by the Legislature of the State of Florida:
13
14 Section 1. Section 893.015, Florida Statutes, is created to
15 read:
16 893.015 Statutory references.—The purpose of this chapter
17 is to comprehensively address drug abuse prevention and control
18 in this state. To this end, unless expressly provided otherwise,
19 a reference in any section of the Florida Statutes to chapter
20 893 or to any section or portion of a section of chapter 893
21 includes all subsequent amendments to chapter 893 or to the
22 referenced section or portion of a section.
23 Section 2. Paragraph (a) of subsection (2) of section
24 893.03, Florida Statutes, is amended to read:
25 893.03 Standards and schedules.—The substances enumerated
26 in this section are controlled by this chapter. The controlled
27 substances listed or to be listed in Schedules I, II, III, IV,
28 and V are included by whatever official, common, usual,
29 chemical, trade name, or class designated. The provisions of
30 this section shall not be construed to include within any of the
31 schedules contained in this section any excluded drugs listed
32 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
33 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
34 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
35 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
36 Anabolic Steroid Products.”
37 (2) SCHEDULE II.—A substance in Schedule II has a high
38 potential for abuse and has a currently accepted but severely
39 restricted medical use in treatment in the United States, and
40 abuse of the substance may lead to severe psychological or
41 physical dependence. The following substances are controlled in
42 Schedule II:
43 (a) Unless specifically excepted or unless listed in
44 another schedule, any of the following substances, whether
45 produced directly or indirectly by extraction from substances of
46 vegetable origin or independently by means of chemical
47 synthesis:
48 1. Opium and any salt, compound, derivative, or preparation
49 of opium, except nalmefene or isoquinoline alkaloids of opium,
50 including, but not limited to the following:
51 a. Raw opium.
52 b. Opium extracts.
53 c. Opium fluid extracts.
54 d. Powdered opium.
55 e. Granulated opium.
56 f. Tincture of opium.
57 g. Codeine.
58 h. Ethylmorphine.
59 i. Etorphine hydrochloride.
60 j. Hydrocodone.
61 k. Hydromorphone.
62 l. Levo-alphacetylmethadol (also known as levo-alpha
63 acetylmethadol, levomethadyl acetate, or LAAM).
64 m. Metopon (methyldihydromorphinone).
65 n. Morphine.
66 o. Oxycodone.
67 p. Oxymorphone.
68 q. Thebaine.
69 2. Any salt, compound, derivative, or preparation of a
70 substance which is chemically equivalent to or identical with
71 any of the substances referred to in subparagraph 1., except
72 that these substances may shall not include the isoquinoline
73 alkaloids of opium.
74 3. Any part of the plant of the species Papaver somniferum,
75 L.
76 4. Cocaine or ecgonine, including any of their
77 stereoisomers, and any salt, compound, derivative, or
78 preparation of cocaine or ecgonine, except that these substances
79 may not include ioflupane (123I).
80 Section 3. This act shall take effect July 1, 2017.